Ammar Muhammad - Concepedia

Author

Ammar Muhammad

Also Known As

A Muhammad, A. A. MUHAMMAD, A. Ali Muhammad, A. Muhammad, A.A. Muhammad, ABDULSALAM MUHAMMAD, Almu Muhammad, Ammar Ali Muhammad, Ammar Muhammad, Muhammad, Ammar

Publications

753

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Centre Hospitalier Universitaire de Liège Inserm Erasmus University Rotterdam University of L'Aquila

About

Ammar Muhammad is an author at Erasmus MC specializing in medicine, cancer research, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	208
2	Endocrinology	2	2	120
3	Pathology	2	2	193
4	Immunology	1	1	105
5	Neuroscience	1	1	105

Ammar Muhammad

Publications

568

Citations

H-Index

Page 1

	Year	Citations
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly Iulia Potorac, Patrick Pétrossians, Adrian Daly, Endocrine Related Cancer Human GrowthT2-weighted Mri SignalImmunologyPathologyEndocrine Oncology	2016	105
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects Adrian Daly, Bo Yuan, Fréderic Fina, Endocrine Related Cancer Xlag Syndrome PatientsSomatic VariantMendelian DisorderGenetic DisorderMedicine	2016	88
Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study) Ammar Muhammad, A. J. van der Lely, Patric J. D. Delhanty, The Journal of Clinical Endocrinology & Metabolism	2017	84
Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study Tineke J van Wesemael, Sofia Ajeganova, Jennifer Humphreys, Arthritis Research & Therapy	2016	64
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression Ammar Muhammad, Eva C Coopmans, Federico Gatto, The Journal of Clinical Endocrinology & Metabolism	2018	58
Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study Ammar Muhammad, Eva C Coopmans, Patric J. D. Delhanty, European Journal of Endocrinology	2018	57
T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly Eva C Coopmans, J.J. Schneiders, Nour El-Sayed, European Journal of Endocrinology	2020	56
Soluble Klotho: a possible predictor of quality of life in acromegaly patients Eva C Coopmans, Nour El-Sayed, Jan Frystyk, Endocrine	2020	16
Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly A. J. van der Lely, Emmanuelle Kuhn, Ammar Muhammad, European Journal of Endocrinology Surgical OncologyOncologyFirst-line Medical TherapyTumour ShrinkagePharmacology	2020	15
Implementation of an infant male circumcision programme, Pakistan Shazia Moosa, Ammar Muhammad, Sohail Asghar Dogar, Bulletin of the World Health Organization	2021	13

Page 1